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EFFECT OF BLACK-BOX WARNING ON TIME TO SWITCH FROM
ANTIDEPRESSANTS TO ANTIPSYCHOTICS AMONG CHILDREN
SUFFERING FROM DEPRESSIVE DISORDERS IN TEXAS
Bhowmik D1, Dwibedi N2, Goyal R1, Chen H1
1University of Houston, Houston, TX, USA, 2University of Houston, HOUSTON, TX, USA
OBJECTIVES: To examine the effect of antidepressant black-box warning on time to
switch to antipsychotics among previous antidepressant users. METHODS: Informa-
tion from the 2003–2004 Medicaid Analytic eXtract (MAX) data from Texas, released 
by Centers for Medicare & Medicaid Services (CMS), were used in the study. Children
aged 6–18 years and diagnosed with depression (ICD 9-CM: 293.xx, 296.xx, 298.xx,
300.xx, 301.xx, 309.xx, 311.xx) were identiﬁ ed. To assess the impact of FDA public
health advisory on antidepressants released in March 2004, patients on antidepres-
sants in February 2004 were considered to be the cases while those in February 2003
were the controls. Medication switch was operationally deﬁ ned as the initiation of an 
antipsychotic prescription within 30 days before the end of the previous antidepressant
prescription. A multivariable Cox proportional hazard model, adjusted for demo-
graphic factors and antidepressant drug classes, was used to examine the association
between black box warning and time to switch to an antipsychotic among the previous 
antidepressant users. RESULTS: There were 14,457 children between 6–18 years, 
diagnosed with depression in 2003, and 23,694 in 2004. Of these patients, 1646 were 
identiﬁ ed as cases affected by black box warning and 1714 were identiﬁ ed as controls. 
The most commonly prescribed antidepressant was sertraline in both 2003 and 2004. 
FDA public health advisory on antidepressants was found to be signiﬁ cantly increase 
the time to switch from antidepressants to antipsychotics [HR  1.413; 95% Conﬁ -
dence Interval (CI): 1.256–1.589]. The shortest time to switch was found among
Hispanics [HR (vs. Whites)  0.851 (95% CI: 0.749–0.967)]. No statistically signiﬁ -
cant association was found between other factors and medication switch. CONCLU-
SIONS: FDA public health advisory on antidepressants was not found to be associated 
with lesser time to switch to antipsychotics. Further studies are required to examine 
treatment discontinuation and augmentation, and switching to other medications 
resulting from black box warning on antidepressants.
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THE EFFECTS OF ANTIDEPRESSANT STEP-THERAPY PROTOCOLS ON 
PHARMACEUTICAL AND MEDICAL UTILIZATION AND EXPENDITURES
Mark TL1, Gibson TB2, Chu BC3, McGuigan K4
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OBJECTIVES: This study examined the effects of step therapy for antidepressants on
prescription drug utilization and spending and other medical care utilization and 
spending. METHODS: Study population employers who had implemented step 
therapy were compared to employers without step therapy using a pre/post design.
Data were from the 2003 through 2006 MarketScan Research database, and the study 
sample consisted of employees and dependents who used antidepressants (n  15,552 
patients whose employer implemented a step therapy protocol; and n  45,244 patients 
in the comparison group without step therapy). Multivariate generalized estimating
equation models were used to estimate the effects of step therapy on medical and 
prescription drug spending and utilization while controlling for important covariates 
and adjusting for clustering by patient. RESULTS: The effects of step therapy on the
number of antidepressant days supplied per antidepressant user was characterized by 
an immediate drop in the number of antidepressant days supplied after implementa-
tion (coefﬁ cient 0.061, p  0.001). However, the number of antidepressant days 
supplied grew with time (coefﬁ cient 0.014 per quarter, p  0.001), and, 5 quarters
after implementation of step therapy, the number of antidepressant days supplied in
step therapy plans began to exceed the days supplied in comparison plans (i.e., in the 
ﬁ fth quarter after implementation the combined effect is 0.061  5*0.014  0.009). 
For antidepressant users, step therapy was associated with an increase in outpatient 
ofﬁ ce visits and inpatient admissions and the increase remained relatively constant 
each quarter after step therapy began. Step therapy was also positively associated with 
the number of emergency room visits and the increase in emergency room visits grew 
with the amount of time elapsed since step therapy was implemented. CONCLU-
SIONS: Rather than just shifting patients to lower cost antidepressants, step therapy 
may have the unintended effect of reducing overall antidepressant use and increasing 
medical care use and costs.
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PREDICTORS OF OUTPATIENTS VISITS AND EMERGENCY ROOM VISITS
IN PATIENTS WITH EARLY PSYCHOTIC ILLNESS
Kolasa K1, Sweitzer DE2
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OBJECTIVES: To predict health care utilization in patients after the ﬁ rst episode of 
psychosis. METHODS: This analysis utilized data from the CAFE study, a 52-week
randomized, double-blind, ﬂ exible-dose, multicenter study of patients with early psy-
chotic illness assigned to treatment with olanzapine, quetiapine, or risperidone. From
the study population, a subgroup of 179 patients stable at 12 weeks (PANNST, 4 and 
Calgary, T9), was selected for further analysis. Socio-demographic, disease-related,
psychosocial factors and neurocognition were measured and their association with
patient health care utilization determined. Neurocognitive composite scores were cal-
culated at 0, 12 and 52 weeks from the neurocognitive battery (CATIE and BACS), 
converted to standardized Z-scores and divided into tertiles. No drug-related analysis
was preformed. Poisson regression, Negative Binomial, Zero-inﬂ ated Negative Bino-
mial models were used to identify signiﬁ cant predictors of resource utilization.
RESULTS: The mean age of patients was 25.6–6.9 years. During study period, 44% of 
patients had any ER visit and 75% any outpatient visit. Signiﬁ cant multipliers (r) of the
expected number of outpatient visits, in addition to regularly scheduled visits, after 12 
weeks included: any previous outpatient visits (r  3.72, p  0.01), age (r  0.965 per
year age, p  0.02), any abnormal movements (r  6.78, p  0.04), and baseline depres-
sion (r  1.167 per point on Calgary, p  0.01). Signiﬁ cant multipliers of the number of 
ER visits after 12 weeks included: any previous ER visits (r  5.22, p  0.01), neuro-
cognition (r  0.46, 1st Tertile vs 3rd Tertile, p  0.01), and alcohol dependency (r 
2.19, p  0.04). CONCLUSIONS: The utilization of additional outpatients and ER
services for patients after ﬁ rst episode of psychosis is associated to a large extent by 
previous use of health care service, drug/alcohol dependency, depression and cognition. 
The strength of these relationships is greater than the impact of illness severity.
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EFFECTS OF FISCAL INCENTIVES AND SOCIOECONOMIC FACTORS 
ON ANTIDEPRESSANT ADHERENCE
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OBJECTIVES: Patient adherence to pharmaceutical therapy is an important factor in
the successful treatment of depression. Previous research has shown anti-depressant
medication adherence associated with patient age, gender, and medical history; physi-
cian specialty; and practice patterns. Socioeconomic factors and ﬁ scal incentives stem-
ming from health plan beneﬁ t designs have also been hypothesized to impact 
adherence. In this study, we examined how patient, physician, and health plan beneﬁ t
design characteristics impact compliance and persistence, two common measures of 
adherence. METHODS: Retrospective database analysis among patients receiving at 
least one prescription for a selected anti-depressant (duloxetine, venlafaxine XR, 
escitalopram, sertraline, paroxetine, ﬂ uoxetine, citalopram, and/or bupropion) 
between October 1, 2004 and September 30, 2005. The study cohort included indi-
viduals, age 18–64, with a recorded depression diagnosis code within 6 months of the 
initial index drug prescription (n  126,889) and continuous beneﬁ t coverage pre- and
post-index date (ﬁ rst recorded prescription date for the index drug). Compliance was
measured as percentage of patients with 365-day medical possession ratio / 80%; 
persistence, as days on therapy (DOT) with index medication. Predictors of 
compliance were assessed with a logistic regression model; persistence, with a Cox 
Proportional Hazards model. RESULTS: Predictors of lower compliance included
African-American race, index drug initiation as second or higher line of therapy or at 
subtherapeutic dosing levels, psychotropic polypharmacy, comorbid pain diagnoses, 
and co-pay level (95% conﬁ dence intervals for odds ratios all 1). Predictors of higher
compliance included older than 45, more than high school education, income $100K, 
and comorbid anxiety (95% conﬁ dence intervals for odds ratios all 1). Similar results 
were obtained when assessing persistence instead of compliance. CONCLUSIONS:
When possible, comparisons of adherence to alternative antidepressant medications 
should be adjusted for elements of beneﬁ t design, socioeconomics, patient demograph-
ics, and physician specialty and treatment patterns.
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OBJECTIVES: Health plans often conduct analysis of patient adherence to alternative 
anti-depressant options using only pharmacy data. This study assesses how various 
factors identiﬁ ed on medical claims and pharmacy data records impact compliance, a 
common measures of adherence. METHODS: Retrospective study of initiators on 
selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and 
SNRIs) during 2005. Study patients (n  251,934) were continuously eligible 6 months
before and 12 months after initiation on their index medication (duloxetine, venla-
faxine XR, citalopram, escitalopram, ﬂ uoxetine, paroxetine, or sertraline). Compli-
ance was deﬁ ned as percentage of patients with 365-day medical possession ratio 
q80%. Analysis was based on chi-square tests and logistic regression. All reported 
differences were statistically signiﬁ cant at p lt 0.01. Conﬁ dence intervals for all 
reported odds ratios were signiﬁ cant at the 95% level. RESULTS: Across all SNRI 
patients, compliance was the same for venlafaxine XR and duloxetine (36%). Among
SNRI patients with diagnosed MDD, however, compliance was greater for duloxetine
(44%) than venlafaxine XR (41%). Across all SSRI patients, compliance was highest 
for citalopram (29%), lowest for escitalopram (26%). Among SSRI patients diagnosed
with MDD, however, compliance was highest for those on paroxetine (33%), lowest
on citalopram (29%). Signiﬁ cant predictors of compliance based on pharmacy claims
data among MDD patients included prior use of antidepressants (OR  1.72) and
initial dosing at sub- or super-therapeutic levels (OR  0.85 and 0.92, respectively). 
Signiﬁ cant predictors based on medical claims data included recent visits to a mental 
health specialist (OR  1.21), a co-morbid diagnosis of GAD (1.20), and the presence
of co-morbid baseline pain (OR  .85). CONCLUSIONS: Measures of medication 
compliance may be impacted by a number of factors, including patient characteristics,
medical history, and physician specialty. Adherence analysis should adjust for relevant 
confounders identiﬁ ed in medical claims, as well as pharmacy data records.
